Safe and Efficacious Prescribing for Chronic Pain in 2025

At the conclusion of this session, the participant should be able to:

• Compare and contrast the 2016 and 2022 CDC opioid prescribing guidelines, including changes in MME thresholds and tapering recommendations.
• Apply evidence-based strategies for opioid prescribing, including patient risk assessment, use of pain scales, and monitoring tools such as PDMP and urine drug screens.
• Interpret the VA/DoD 2022 guidelines and their implications for opioid initiation and long-term use in chronic non-cancer pain.
• Evaluate the role of buprenorphine as a safer alternative to full agonist opioids in chronic pain management.

ACCREDITATION

The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this activity for a maximum of 1 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.

GRIEVANCE POLICY STATEMENT

It is the policy of the POMA that any physician dissatisfied with the CME program will be issued a refund upon request, and no CME credits will be reported to the AOA.  Complaints on Evaluation Forms are also taken into consideration when planning future CME programs and may lead to changes in the format or content."  If you have any questions or concerns about this educational experience, you may call the POMA office at (717) 939-9318 or send an email message to cme@poma.org.  All questions or concerns will be addressed promptly.